4 Most Undervalued Stocks Near Their 52-Week Lows

Below, we’ve unearthed four deeply undervalued stocks trading near their 52-week lows … and the upside potential on some of these is hard to ignore.

One could have nearly 45% upside according to Wall Street. Another may be selling for substantially less than it’s actually worth. Yet investors are still leaving these stocks behind even as the businesses underneath them beat expectations, grow profits, and in some cases dramatically outgrow their industries.

A note from our sponsors...

Please read the offering circular at invest.modemobile.com. This is a paid advertisement for Mode Mobile's Regulation A+ Offering.

Of course, a falling stock does not automatically make it a bargain. Half the clearance rack is junk for a reason. The trick is separating the real deals from the value traps.

These four stand out because the fundamentals suggest the market may be underestimating what they’re worth.

1. CHAGEE Holdings (CHA): The Beaten-Down Grower

CHAGEE is about as beaten down as they come.

The company operates a fast-growing premium teahouse brand out of China. Think of it as a tea-focused version of the big coffee chains, with thousands of locations and a modern, tech-forward ordering setup.

But investors have punished the stock. Shares have fallen more than 50% over the past year and remain near the lower end of their 52-week range.

That kind of drop scares people off. It feels like the party already ended.

But look at what the business is doing underneath the share price.

CHAGEE has expanded aggressively, growing beyond 7,000 teahouses and increasing its store base at a double-digit clip. Management has also guided for a rebound in revenue and profitability and backed that confidence with a fresh share buyback.

Looking ahead, earnings are forecast to grow 46.47% annually, compared with an industry average of about 14%.

Wall Street is starting to take notice, too. The analyst consensus sits at Buy, while JPMorgan's price target points to substantial upside from current levels. (See analyst forecasts here.)

The quantitative picture adds another layer. CHAGEE earns a B rating from WallStreetZen's Zen Ratings system, placing it in the top 6% of more than 4,000 stocks analyzed.

Its Component Grades reveal where the strength comes from: Growth ranks in the top 20%, Sentiment in the top 18%, Financials in the top 14%, and Value in the top 5%.

The weak spot is Safety, which isn’t surprising for a freshly public Chinese growth stock. But with elite value, thousands of new stores, and Wall Street bullish, there’s a lot to like at this price.

CHAGEE is the beaten-down growth story on this list.

Research CHA on WallStreetZen

2. Phibro Animal Health (PAHC): 10 Straight Earnings Beats

Phibro Animal Health makes the medicines, vaccines, and nutrition that keep livestock and pets healthy. It’s an essential, global business hiding in one of the least glamorous corners of healthcare, which may be exactly why this bargain has slipped under the radar.

The stock hit a high of roughly $60 before getting hammered, falling more than 40%.

So what spooked investors?

Despite strong operating results, investors have had reasons for caution, including Phibro's debt load following a major acquisition. But the underlying business has continued to deliver.

Phibro has sailed past Wall Street's earnings expectations for 10 consecutive quarters. That's not a lucky break. It's a consistent pattern of outperforming analyst estimates.

And the outlook remains strong. Earnings are forecast to grow 22.94% annually, roughly 50% faster than the industry.

But even that isn't the most interesting part.

Phibro trades at a PEG ratio well below 1. For a business growing at this pace, that suggests investors may be paying surprisingly little for its expected growth.

Wall Street coverage remains thin, which adds to the under-the-radar story.

The quantitative picture backs up the value thesis. Phibro earns a B overall rating, while Value stands out as its strongest Component Grade.

That’s the appeal here. The stock has lost momentum, but the business continues to beat expectations and analysts expect earnings to keep growing at an above-industry pace.

Phibro is the quiet compounder hiding in plain sight.

Research PAHC on WallStreetZen

3. Amphastar Pharmaceuticals (AMPH): A Stock Near Its Lows After a Big Quarter

Amphastar Pharmaceuticals is a specialty pharma company that makes injectable and inhalation medicines, including complex, hard-to-copy drugs that hospitals and pharmacies rely on every day.

It isn't a household name, but it is a real, profitable business with deep roots.

The stock remains near the lower end of its 52-week range. But you wouldn’t know it from its latest results.

Amphastar just reported $183.9 million in quarterly revenue, beating Wall Street's expectations. Adjusted profit came in nearly 50% above estimates.

When a stock is sitting near its lows while the business is delivering numbers like that, you have to wonder whether the market has gotten it wrong.

The valuation makes that question even harder to ignore.

Amphastar trades at a PEG ratio below 0.5. A PEG that low suggests investors are paying relatively little for the company's expected earnings growth.

And those growth expectations aren't trivial. Analysts expect Amphastar's earnings to grow considerably faster than the industry average.

There is another interesting wrinkle in the analyst picture. While the broader consensus has been more cautious, one of the highest-rated analysts covering the stock carries a Buy rating with a price target implying substantial upside.

The Component Grades reveal why Amphastar deserves attention. Sentiment ranks in the top 19%, Growth in the top 16%, Financials in the top 15%, and Safety in the top 11%. Then there’s the standout: Value ranks in the top 1% of all stocks.

Put it all together, and this isn't simply a struggling company that happens to be cheap. The fundamentals are strong across several important measures, while the valuation remains exceptionally low.

That gap between the business and the stock price is what makes Amphastar interesting.

Research AMPH on WallStreetZen

4. Omnicell (OMCL): The Business Is Already Fighting Back

Omnicell is a little different from the other names on this list. While several remain pinned near the bottom, this one has already shown signs of fighting its way back.

If you've ever picked up a prescription, there is a good chance Omnicell technology was working somewhere behind the scenes.

The company builds automation systems for hospitals and pharmacies, including medication-dispensing machines, tracking systems, and software designed to make medication management safer and more efficient.

So why did investors sour on it?

The stock sold off after a recent earnings report even though the numbers underneath were strong. Earnings improved substantially from a year earlier, revenue beat expectations, and management raised its full-year earnings outlook.

Investors instead focused on softer guidance for the upcoming quarter and hit the sell button.

That disconnect is what makes the stock interesting.

Omnicell's longer-term growth outlook remains impressive. Earnings are forecast to grow about 41% annually, roughly twice the industry average.

Wall Street also sees considerable upside. The analysts covering Omnicell unanimously rate it a Strong Buy, with their average price target implying roughly 45% upside at the time of the original analysis.

The Component Grades tell a similar story. Sentiment ranks in the top 19%, Growth in the top 11%, Safety in the top 9%, and Value in the top 8%.

That's the sweet spot for a value stock: an attractive price without bargain-bin fundamentals. You have growth, relative stability, positive investor sentiment, and a compelling valuation all working together.

Omnicell also earns an A overall rating from WallStreetZen's Zen Ratings system.

For investors hunting for situations where the market may have overreacted to short-term concerns, that combination deserves attention.

Research OMCL on WallStreetZen

The Bottom Line

These four stocks have very different businesses, but they share the same basic setup: their share prices have taken a beating while important parts of the underlying businesses continue to perform.

CHAGEE gives you a beaten-down growth story with an aggressive expansion plan. Phibro combines a steep pullback with 10 consecutive earnings beats. Amphastar pairs an unusually low valuation with a recent earnings surprise. And Omnicell offers strong projected earnings growth and significant potential upside according to Wall Street.

That doesn't mean every beaten-down stock will rebound. Sometimes a stock near its 52-week low deserves to be there.

But when the price falls while earnings, growth, valuation, or other fundamentals tell a very different story, you may have found something more interesting than a falling knife.

You may have found a business the market is underestimating.

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.